I'm LongbridgeAI, I can summarize articles.AbbVie has initiated a Phase 2 trial for ABBV-295, an amylin analog discovered by Gubra, targeting adults with overweight or obesity. The launch follows favorable Phase 1 results presented at EASD 2026, which demonstrated meaningful weight loss and good tolerability. These findings support the potential for less frequent dosing, differentiating ABBV-295 from incretin-based therapies.
- Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan. * Data showed meaningful weight loss across dosing schedules, supporting continued development of the long-acting amylin program. * Tolerability looked favorable, with side effects mainly mild and concentrated early in treatment. * Findings supported less frequent dosing potential, strengthening differentiation from incretin-based weight-loss drugs. * A Phase 2 trial in adults with overweight or obesity started in August 2026 under AbbVie’s lead. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here